|
시장보고서
상품코드
2084834
피부근염 치료제 시장 : 약제 유형별, 투여 경로별, 유통 채널별, 지역별Dermatomyositis Drug Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
피부근염 치료제 시장은 2026년에 9억 1,200만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 12억 1,630만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 4.2%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 9억 1,200만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 4.20% | 2033년 시장 규모 예측 : | 12억 1,630만 달러 |
피부근염(DM)은 근육과 피부 모두에 영향을 미치는 희귀한 염증성 근육 질환입니다. 피부근염은 인종, 성별, 연령에 관계없이 누구에게나 발병할 가능성이 있습니다. 소아기에는 남녀의 발병률이 비슷하지만, 성인기가 되면 여성에게서 더 많이 나타납니다. DM의 정확한 원인은 밝혀지지 않았으나, 유전적 소인을 가진 개인에게서 외부 요인(악성 종양, 약물, 감염증 등)에 의해 유발되는 면역 매개 과정에 기인하는 것으로 여겨집니다. 피부근염은 전신성 홍반성 루푸스, 류마티스 관절염, 경피증, 쇼그렌 증후군, 혼합성 결합조직 질환 등 다른 결합조직 질환과 동반될 수 있습니다.
시장 역학
전 세계 피부근염 치료제 시장에서 사업을 운영하는 주요 기업은 제품 승인 등 성장 전략의 도입에 주력하고 있으며, 이는 예측 기간 중 시장 성장을 촉진할 것으로 전망됩니다. 예를 들어 2018년 7월, 희귀·만성·중증 염증성 및 섬유화성 질환 치료를 위한 신약 개발 및 상용화에 주력하는 3상 임상시험 단계의 제약 기업인 Corbus Pharmaceuticals Holdings, Inc.는 미국 식품의약국(FDA)이 이 회사가 개발한 새로운 합성 경구용 엔도카나비노이드 모방제인 레나바삼에 대해 피부근염 치료제로 희귀질환용 의약품 지정을 부여했다고 발표했습니다. 또한 주요 기업의 피부근염 치료를 위한 연구개발 활동이 활발해짐에 따라 예측 기간 중 시장 성장을 촉진할 것으로 전망됩니다. 예를 들어 2019년 10월 21일, 바이오의약품 기업인 CSL 베링은 피부근염(DM) 성인 환자를 대상으로 IgPro20(피하 투여용 면역글로불린, 히젠트라)의 유효성, 안전성 및 약동학을 평가하기 위한 3상 임상시험을 시작했습니다. 이 시험은 2024년 2월에 완료될 예정입니다.
본 시험의 주요 특징.
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 주요 지표(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)를 바탕으로 전 세계 피부근염 치료제 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 피부근염 치료제 시장 보고서'는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 피부근염 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 피부근염 치료제 시장 : 약제 유형별, 2021-2033년
제5장 세계의 피부근염 치료제 시장 : 투여 경로별, 2021-2033년
제6장 세계의 피부근염 치료제 시장 : 유통 채널별, 2021-2033년
제7장 세계의 피부근염 치료제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.07.14Dermatomyositis Drug Market is estimated to be valued at USD 912 Mn in 2026 and is expected to reach USD 1,216.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 912 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.20% | 2033 Value Projection: | USD 1,216.3 Mn |
Dermatomyositis (DM) is a rare inflammatory muscle disease that affects both the muscles as well as the skin. Dermatomyositis can strike people of all races, genders, and ages. Although, both males and females are affected equally in childhood, it is more common in females in adults. The exact cause of DM is unknown but it is believed to result from an immune-mediated process triggered by outside factors (e.g. malignancy, drugs, and infectious Drug Types) in genetically predisposed individuals. Dermatomyositis can occur with other connective tissue disorders such as systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren's syndrome, and mixed connective tissue disease.
Market Dynamics
Key players operating in the global dermatomyositis drug market are focusing on adoption of growth strategies such as product approvals which is expected to drive the market growth during the forecast period. For instance, in July 2018, Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced that the U.S. Food and Drug Administration had granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis. Moreover, increasing research and development activities by key players for the treatment of dermatomyositis which is expected to drive the market growth over the forecast period. For instance, on October 21, 2019, CSL Behring,a biopharmaceutical company initiated phase 3 Study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in adults with dermatomyositis (DM). The study is estimated to be completed in February 2024.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global dermatomyositis drug market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceuticals USA, Inc., Hikma Pharmaceuticals PLC, Asahi Kasei Corporation., Octapharma USA, Healthcare Pharmaceuticals Limited., Zydus Cadila, Alkem Laboratories Ltd, Apotex Inc, Eli Lilly and Co, and F.Hoffman-La Roche Ltd
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global dermatomyositis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis drug market
Market Segmentation
- By Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
- Corticosteroids
- Immunosuppressive Agents
- Others
- By Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Oral
- Topical
- Others
- By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Region Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Pfizer Inc.
- Teva Pharmaceuticals USA, Inc.
- Hikma Pharmaceuticals PLC
- Asahi Kasei Corporation.
- Octapharma USA
- Healthcare Pharmaceuticals Limited.
- Zydus Cadila
- Alkem Laboratories Ltd
- Apotex Inc.
- Eli Lilly and Co
- Hoffman-La Roche Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Epidemiology
- PEST Analysis
- Collaboration and Acquisition
- Porters Analysis
- Pipeline Analysis
4. Global Dermatomyositis Drug Market, By Drug Type, 2021-2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Immunosuppressive Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
5. Global Dermatomyositis Drug Market, By Route of Administration, 2021-2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Dermatomyositis Drug Market, By Distribution Channel, 2021-2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
7. Global Dermatomyositis Drug Market, By Region, 2021-2033, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2021-2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021-2033, (US$ Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceuticals USA, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hikma Pharmaceuticals PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Asahi Kasei Corporation.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Octapharma USA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Healthcare Pharmaceuticals Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alkem Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Apotex Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Eli Lilly and Co
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- F. Hoffman-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
9. Section
- Research Methodology
- About us
